Professor Snyder received his doctorate in clinical neuropsychology and behavioral neuroscience from Michigan State University in 1992, following a residency at Long Island Jewish Medical Center. Dr. Snyder was awarded the 1992 Wilder Penfield Fellowship by the American Epilepsy Society and Epilepsy Foundation of America, and he served as a Clinical Neurosciences Fellow in the NIMH Clinical Research Center for the Study of Schizophrenia at Hillside Hospital (Albert Einstein College of Medicine) in 1992 and 1993.
Dr. Synder is a Professor of Biomedical and Pharmaceutical Sciences, University of Rhode Island. Dr. Snyder is the Founding Editor-in-Chief for Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring (an Alzheimer’s Association open access journal), and he manages a robust research program. His academic interests span across a range of topics in neuropharmacology, neurophysiology, history of neuroscience and research ethics; his clinical interests are currently focused on the topics of aging and dementia. From 1998 through 2005, Dr. Snyder was employed as a scientist, clinician, and director at Pfizer Global Research & Development – Groton Laboratories (Connecticut, USA) – the largest research laboratory of Pfizer Inc. Dr. Snyder was responsible for the identification and development of novel clinical technologies and biomarkers for the CNS therapeutic area at Pfizer. As a Director and Early Clinical Leader at Pfizer, Dr. Snyder led the development of novel compounds for the treatment of schizophrenia and Alzheimer’s disease.